ClinicalTrials.gg
Not yet recruitingNCT07856108Updated Oct 2, 2026

Effects of PNB Timing on Postoperative Delirium for Hip Fracture

An observational study in Delirium - Postoperative, sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. Not yet recruiting at 1 site in Canada. Open to participants aged 65 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Observational

How we know

Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
120
Ages
65 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Emergence Delirium with a site in Canada — 5 open to participants now, 6 under way, none of them phase 3. Emergence Delirium · Canada.

Started
2026
the only one that year
Observational
4 of 16
1 open now
Registered
16th of 16
by date
Lead sponsor
1 of 16
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Among the 16 studies in Emergence Delirium with a site in Canada, this one is the only one that started in 2026, is one of 4 observational ones, and was the 16th registered.

Emergence Delirium

753 studies on the registry are indexed under Emergence Delirium; 261 are open to participants now.

Browse Emergence Delirium studies →

Open to participants now

5 of the 16 studies in Emergence Delirium with a site in Canada are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 141 Emergence Delirium studies recruiting now, 78 (55%) set no upper age limit and 43 (30%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 65 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Emergence Delirium with a site in Canada, or all of them as a file.
02

Study summary

Hip fracture is a common cause of hospitalization in older adults and is associated with substantial pain and a high risk of delirium. Peripheral nerve blocks (PNBs) can provide effective, opioid-sparing analgesia, but the relationship between the timing of PNB administration after hospital presentation and subsequent delirium is not well established.

This prospective, longitudinal, dual-centre pilot study will evaluate the association between the timing of PNB administration and the development and severity of delirium in adults aged 65 years or older admitted with a hip fracture requiring surgical repair and a planned PNB. Approximately 60 patient participants will be enrolled at University Hospital and Victoria Hospital, London Health Sciences Centre. Caregiver participants will also be recruited to provide information on baseline and follow-up cognitive and functional status.

Participants will receive standard clinical care; the study will not determine or alter the timing or type of PNB, surgery, analgesia, or other treatment. PNB timing will be classified as early (\<6 hours after hospital presentation), intermediate (6 to 12 hours), or late (>12 hours). The primary outcome is new-onset delirium during hospitalization, assessed using the 4 A's Test (4AT). Delirium severity will also be evaluated using serial 4AT scores collected during the hospital stay. The investigators hypothesize that earlier PNB administration will be associated with a lower incidence and severity of delirium.

Secondary and exploratory outcomes include perioperative opioid consumption, hospital length of stay, 30-day mortality, delirium burden, and functional and caregiver-reported delirium outcomes at 3 months. The study will also assess recruitment feasibility and generate preliminary estimates of delirium incidence and effect size to inform the design and sample-size calculation of a future adequately powered prospective study.

Read the detailed description

Delirium is a common complication among older adults hospitalized with hip fracture and is associated with adverse clinical outcomes. Acute pain is a potentially modifiable contributor to delirium, while opioid analgesics, although commonly used for hip fracture pain, may themselves contribute to adverse effects such as sedation and worsening cognitive dysfunction. Peripheral nerve blocks (PNBs), including fascia iliaca and femoral nerve blocks, provide effective regional analgesia and may reduce opioid requirements. However, the relationship between the timing of PNB administration after hospital presentation and the subsequent development and severity of delirium remains unclear.

This is a prospective, longitudinal, dual-centre pilot study designed to evaluate the association between the timing of PNB administration and delirium outcomes in adults aged 65 years or older admitted with a hip fracture requiring surgical repair and planned use of a PNB. The study will be conducted at the University Hospital and Victoria Hospital campuses of London Health Sciences Centre in London, Ontario, Canada.

The study is observational. Participation will not determine or alter the timing or type of PNB, surgical management, analgesic therapy, or other aspects of clinical care. Participants will receive standard hospital care, including multimodal analgesia, PNBs, surgery, and medical management as clinically indicated. PNBs may be performed in the Emergency Department or Block Room as part of routine clinical care. Delirium and cognitive assessments that are routinely obtained during hospitalization will be used for study purposes, together with additional study data collected from participants, caregivers, and the electronic medical record.

Approximately 60 patient participants will be recruited during the planned 2-month pilot recruitment period using consecutive convenience sampling. Approximately 60 caregiver participants will also be recruited to provide information regarding the patient's baseline and follow-up cognitive and functional status. The pilot sample size is based on feasibility rather than a formal statistical power calculation. The study is intended to provide preliminary estimates of recruitment feasibility, delirium incidence, and the magnitude and direction of associations between PNB timing and delirium outcomes to inform the design and sample-size calculation of a future adequately powered prospective study.

The primary exposure of interest is the elapsed time between hospital presentation with hip fracture and administration of the PNB. PNB timing will be evaluated using three prespecified categories:

Early PNB: less than 6 hours after hospital presentation; Intermediate PNB: 6 to 12 hours after hospital presentation; and Late PNB: more than 12 hours after hospital presentation.

Actual elapsed time from hospital presentation to PNB administration will also be evaluated as a continuous exposure to explore whether increasing delay to PNB is associated with delirium outcomes.

The primary outcome is the development of new-onset delirium during hospitalization. Delirium will be assessed using the 4 A's Test (4AT), a brief screening instrument evaluating alertness, orientation, attention, and acute change or fluctuation in mental status. A 4AT score of 4 or greater is considered consistent with possible delirium. New-onset delirium is defined as a 4AT score of 4 or greater occurring after admission in a participant with a baseline 4AT score below 4, or a new increase in 4AT score consistent with delirium in a patient who did not have delirium at admission. Participants with delirium at admission will not be included in the primary analysis of new-onset delirium.

The study will also evaluate the severity and overall burden of delirium during hospitalization. Serial 4AT scores will be obtained as part of routine clinical care and followed until discharge. Measures of delirium burden may include the maximum 4AT score, mean daily 4AT score, number and proportion of assessed hospital days with a 4AT score of 4 or greater, time from admission to the first delirium-positive assessment, time from PNB administration to the first delirium-positive assessment, and duration of delirium.

Baseline cognitive status will also be characterized using the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE), which obtains caregiver or informant information regarding changes in cognitive function over time. Baseline functional status will be assessed using the Older Americans Resources and Services Activities of Daily Living (OARS ADL) instrument. The Family Confusion Assessment Method (Fam-CAM), a caregiver-administered delirium screening tool, will be used to obtain caregiver-reported information regarding delirium.

In addition to delirium outcomes, data collected will include patient age, biological sex, relevant medical comorbidities, fracture type, type of surgical procedure, time from hospital admission to surgery, type of PNB, and opioid exposure. PNB characteristics will include the type of block and, where applicable, whether the technique involved a single injection or continuous catheter.

Perioperative opioid consumption will be examined as a secondary outcome. Opioid doses will be converted to standardized intravenous morphine-equivalent doses using a prespecified institutional conversion method. Opioid use may be summarized over clinically relevant periods, including admission to PNB administration, PNB administration to surgery, the intraoperative period, the postoperative period, and the total hospitalization where data are available. Opioid exposure will be compared among the early, intermediate, and late PNB groups.

Other secondary outcomes include hospital length of stay and 30-day mortality. Length of stay will be measured from hospital admission to discharge. Thirty-day mortality will be determined following hospital admission and is expected to be analyzed primarily descriptively because of the pilot sample size.

Participants will also undergo follow-up at approximately 3 months after hospital discharge. Functional status will be reassessed using the OARS ADL instrument, allowing evaluation of change from baseline functional status. Caregiver-reported delirium or cognitive symptoms will be assessed using the Fam-CAM. These follow-up measures will be compared across PNB timing groups on an exploratory basis.

The primary analysis will estimate the association between PNB timing and new-onset delirium. Delirium incidence will be summarized within each PNB timing group. Where supported by the number of outcome events, multivariable logistic regression will be used to estimate the association between PNB timing and delirium while accounting for clinically relevant potential confounders. Potential confounding variables may include age, biological sex, baseline cognitive status, baseline functional status, relevant comorbidity burden, opioid exposure, fracture type, time to surgery, and PNB type. Because this is a pilot study with a limited sample size, the number of variables included in adjusted models will be restricted to reduce the risk of model overfitting.

Longitudinal delirium severity will be evaluated using repeated 4AT measurements obtained during hospitalization. Where appropriate, mixed-effects modelling will be used to account for correlation among repeated assessments within the same participant and to examine differences in delirium trajectories among PNB timing groups. Exploratory analyses will also examine the relationship between actual time to PNB administration and measures of delirium severity and burden.

Because the timing of delirium onset may be clinically relevant, exploratory time-to-event analyses may be conducted using hospital admission as the starting point and the first occurrence of new-onset delirium as the event. Participants who do not develop delirium will be censored at hospital discharge. If the number of events and sample size permit, sensitivity analyses may account for PNB administration as a time-dependent exposure.

All statistical analyses are exploratory because this is a pilot study and no formal efficacy-based sample-size calculation has been performed. Interpretation will therefore emphasize the magnitude, direction, and precision of estimated associations, including confidence intervals, rather than statistical significance alone. Results will be used to assess study feasibility and to inform outcome selection, analytic methods, and sample-size requirements for a future adequately powered prospective study evaluating the relationship between the timing of PNB administration and delirium in older adults with hip fracture.

The study hypothesis is that earlier PNB administration, particularly within 6 hours of hospital presentation, will be associated with a lower incidence and severity of delirium compared with later PNB administration.

03

Conditions studied

  • Delirium - Postoperative

Keywords

  • Anesthesia
  • Delirium
  • Peripheral nerve block
  • Hip fracture
04

Who can participate

Ages eligible
65 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patient Participants: Patients admitted for hip fractures requiring surgery with the use of a PNB.

Caregiver Participants: Caregivers of patients admitted for hip fractures requiring surgery with the use of a PNB.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patient Participant Inclusion Criteria

  1. Patients admitted to for hip fractures requiring surgery with the use of a PNB.
  2. Age ≥65 years.
  3. Able to give consent to participate in this project.
  4. Able to converse in English.

Caregiver Inclusion Criteria

  1. Able to complete questionnaires assessing the functional physical and mental status of the patient participant.
  2. Able to converse in English

Exclusion criteria

Exclusion Criteria:

Patient Participant Exclusion Criteria

  1. Patient refusal to participate in this project.
  2. Patient with a 4 4AT score on admission
  3. Unable to give consent.
  4. Preexisting cognitive impairment preventing delirium assessment, including (but not limited to) advanced dementia.

Caregiver Exclusion Criteria

1. None

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
120 participants (estimated)
Patient registry
No

Groups and cohorts

  • Peripheral Nerve Block

    Peripheral nerve block administered for hip fracture pain control

    Procedure: Peripheral Nerve Block for Hip Fracture

Interventions

  • ProcedurePeripheral Nerve Block for Hip Fracture

    Peripheral Nerve Block for Hip Fracture

06

What researchers measure

Primary outcomes

  1. Determination of the impact of peripheral nerve block (PNB) timing on the incidence of new-onset delirium in hip fracture patients.

    Early administration of the PNB will be a PNB placed less than 6 hours after presenting to the hospital with a hip fracture. Intermediate administration of PNB would be within 6 to 12 hours, and late administration of PNB would be more than 12 hours after presentation to the hospital with a hip fracture. New-onset delirium is defined as a 4AT score ≥4 occurring after hospital admission or during the hospital stay in a patient who had a 4AT score \<4 at baseline, or a new increase in 4AT score consistent with delirium in a patient without delirium at admission. This will be measured by analyzing the results of the cognitive and delirium testing questionnaires and determining if there is an association between the occurrence of delirium and timing of PNB administration.

    Time frame: 3 months

Secondary outcomes

  1. Association between the timing of PNB administration (early versus intermediate versus late) and the severity of delirium in patients with hip fracture.

    This will be measured by analyzing the results of the cognitive and delirium testing questionnaires and determining if there is an association between the occurrence of delirium and timing of PNB administration.

    Time frame: 3 months

  2. Determine impact of PNB administration timing on opioid consumption

    This will be measured by comparing opioid consumption between participants who received early vs. intermediate vs. late PNBs.

    Time frame: 3 months

  3. Duration of hospital stay

    This will be measured by recording how long the participant remained in hospital following surgery.

    Time frame: 3 months

  4. Occurrence of mortality at 30 days

    This will be measured by recording (yes/no) if the participant died within 30 days of surgery.

    Time frame: 30 days

  5. Determination of recruitment feasibility

    To assess recruitment feasibility and provide preliminary effect size estimates to inform the design and sample size calculation of a future adequately powered study. Recruitment feasibility will be measured by assessing the number of participants recruited over a defined period of time. Future sample sizes estimates will be measured by determining the significance of data analyzed within the pilot cohort

    Time frame: 2 years

07

Study locations

1 site
08

References and documents

Publications

  • McGinn R, Talarico R, Hamiltoon GM, Ramlogan R, Wijeysundra DN, McCartney CJL, McIsaac DI. Hospital-, anaesthetist-, and patient-level variation in peripheral nerve block utilisation for hip fracture surgery: a population-based cross-sectional study. Br J Anaesth. 2022 Jan;128(1):198-206. doi: 10.1016/j.bja.2021.10.011. Epub 2021 Nov 16. PubMed 34794768 ↗
  • Mouzopoulos G, Vasiliadis G, Lasanianos N, Nikolaras G, Morakis E, Kaminaris M. Fascia iliaca block prophylaxis for hip fracture patients at risk for delirium: a randomized placebo-controlled study. J Orthop Traumatol. 2009 Sep;10(3):127-33. doi: 10.1007/s10195-009-0062-6. Epub 2009 Aug 19. PubMed 19690943 ↗
  • Guay J, Parker MJ, Griffiths R, Kopp S. Peripheral nerve blocks for hip fractures. Cochrane Database Syst Rev. 2017 May 11;5(5):CD001159. doi: 10.1002/14651858.CD001159.pub2. PubMed 28494088 ↗
  • Inouye SK, Westendorp RG, Saczynski JS. Delirium in elderly people. Lancet. 2014 Mar 8;383(9920):911-22. doi: 10.1016/S0140-6736(13)60688-1. Epub 2013 Aug 28. PubMed 23992774 ↗
  • American Geriatrics Society Expert Panel on Postoperative Delirium in Older Adults. American Geriatrics Society abstracted clinical practice guideline for postoperative delirium in older adults. J Am Geriatr Soc. 2015 Jan;63(1):142-50. doi: 10.1111/jgs.13281. Epub 2014 Dec 12. PubMed 25495432 ↗
  • Brown CH 4th, LaFlam A, Max L, Wyrobek J, Neufeld KJ, Kebaish KM, Cohen DB, Walston JD, Hogue CW, Riley LH. Delirium After Spine Surgery in Older Adults: Incidence, Risk Factors, and Outcomes. J Am Geriatr Soc. 2016 Oct;64(10):2101-2108. doi: 10.1111/jgs.14434. Epub 2016 Oct 3. PubMed 27696373 ↗
  • Xue P, Wu Z, Wang K, Tu C, Wang X. Incidence and risk factors of postoperative delirium in elderly patients undergoing transurethral resection of prostate: a prospective cohort study. Neuropsychiatr Dis Treat. 2016 Jan 12;12:137-42. doi: 10.2147/NDT.S97249. eCollection 2016. PubMed 26834475 ↗
  • Jin Z, Hu J, Ma D. Postoperative delirium: perioperative assessment, risk reduction, and management. Br J Anaesth. 2020 Oct;125(4):492-504. doi: 10.1016/j.bja.2020.06.063. Epub 2020 Aug 11. PubMed 32798069 ↗
  • Kosar CM, Tabloski PA, Travison TG, Jones RN, Schmitt EM, Puelle MR, Inloes JB, Saczynski JS, Marcantonio ER, Meagher D, Reid MC, Inouye SK. EFFECT OF PREOPERATIVE PAIN AND DEPRESSIVE SYMPTOMS ON THE DEVELOPMENT OF POSTOPERATIVE DELIRIUM. Lancet Psychiatry. 2014 Nov;1(6):431-436. doi: 10.1016/S2215-0366(14)00006-6. PubMed 25642413 ↗
  • Ding X, Gao X, Chen Q, Jiang X, Li Y, Xu J, Qin G, Lu S, Huang D. Preoperative Acute Pain Is Associated with Postoperative Delirium. Pain Med. 2021 Feb 4;22(1):15-21. doi: 10.1093/pm/pnaa314. PubMed 33040141 ↗
  • Watne LO, Idland AV, Fekkes D, Raeder J, Frihagen F, Ranhoff AH, Chaudhry FA, Engedal K, Wyller TB, Hassel B. Increased CSF levels of aromatic amino acids in hip fracture patients with delirium suggests higher monoaminergic activity. BMC Geriatr. 2016 Aug 2;16:149. doi: 10.1186/s12877-016-0324-0. PubMed 27484129 ↗

Individual participant data

Plan to share: No — No plan as not applicable.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jan 2028, 14 months later.

Of 180 non-industry observational studies under Emergence Delirium, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 14 months is below that.

Counting every sponsor, half of 180 studies reached it within 21 months; a quarter within 10 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2026
First posted
Oct 2, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
Jan 1, 2028
CompletionEst.
Jan 1, 2028
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07856108
Responsible party
Abhijit Biswas (Anesthesiologist, Associate Professor, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's) — Principal investigator
First posted
Oct 2, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Jan 1, 2028 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Oct 2, 2026

Study contacts

Abhijit Biswas, MD
Contact
abhijit.biswas@lhsc.on.ca
5196858500 ext. Ext. 55956
Abhijit Biswas, MD
principal investigator · London Health Sciences Centre and Western University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion